Azacitidine as maintenance therapy in pediatric <i>de novo</i> acute myeloid leukemia.

For the IR subgroup, azacitidine maintenance (n=17) demonstrated a numeric improvement in EFS, OS and CIR compared to observation (n=24), though differences did not reach statistical significance (EFS: 85.1% vs. 69.3%, HR, 0.371, 95% CI, 0.099–1.387, p = 0.198; OS: 92.9% vs. 81.6%, HR, 0.335, 95% CI, 0.057–1.972, p = 0.304; CIR:14.9% vs. 26.9%, HR, 0.444, 95% CI, 0.110–1.802, p = 0.305) ( Figure 3A–C ).

also in 111,027 other papers